---
title: Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.
nct_id: NCT02063113
overall_status: TERMINATED
phase: NA
sponsor: Nantes University Hospital
study_type: INTERVENTIONAL
primary_condition: Multiple Myeloma in Older Patients
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02063113.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02063113"
ct_last_update_post_date: 2023-05-23
last_seen_at: "2026-05-12T06:54:38.718Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.

**NCT ID:** [NCT02063113](https://clinicaltrials.gov/study/NCT02063113)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** inclusion difficulty
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 48
- **Lead Sponsor:** Nantes University Hospital
- **Conditions:** Multiple Myeloma in Older Patients
- **Start Date:** 2014-05-19
- **Completion Date:** 2018-11-28
- **CT.gov Last Update:** 2023-05-23

## Brief Summary

The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient. During the comprehensive geriatric assessment realized before the decision-treatment, the following data are recorded and their impact in the therapeutic changes will also be analysed: comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.

## Eligibility

- **Minimum age:** 70 Years
- **Maximum age:** 100 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients aged 70 years and older
* Patients referred for a assessment of a newly diagnosed multiple myeloma
* Patients for who the initial therapy proposed is either melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib or included in a phase 3 trial.
* Patients who provide informed written consent

Exclusion Criteria:

* Patients who refuse the study
* Patients who won't have therapy
* Patients can't respond to geriatric assessment because of severe cognitive disorder
* Patients with a legal guardian
```

## Arms

- **NA/NA** (NO_INTERVENTION)

## Interventions

- **Vulnerability and therapeutic changes in older patients with multiple myeloma.** (OTHER)

## Primary Outcomes

- **The occurrence of the events** _(time frame: 6 MONTHS)_ — The primary outcome is either :

* early interruption of treatment
* dose reduction \> 20% during treatment
* discontinuous treatment

These outcomes will be measured every 6 months during the 2 years of follow up

## Secondary Outcomes

- **Type of Vulnerability** _(time frame: 6 MONTHS)_
- **Therapeutic changes** _(time frame: 6 MONTHS)_
- **Toxicity during treatment** _(time frame: 6 months)_
- **Progression to 1 and 2 years** _(time frame: 1 year/2year)_
- **Complete response at 1 and 2 years** _(time frame: 1 year/2 years)_

## Locations (2)

- CHD Vendée La Roche sur Yon, La Roche-sur-Yon, France
- CHU de Nantes, Nantes, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chd vendée la roche sur yon|la roche-sur-yon||france` — added _(2026-05-12)_
- `locations.chu de nantes|nantes||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02063113.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02063113*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*